View Item 

Show simple item record

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

dc.contributor.authorOnel, Karen B.
dc.contributor.authorHorton, Daniel B.
dc.contributor.authorLovell, Daniel J.
dc.contributor.authorShenoi, Susan
dc.contributor.authorCuello, Carlos A.
dc.contributor.authorAngeles-Han, Sheila T.
dc.contributor.authorBecker, Mara L.
dc.contributor.authorCron, Randy Q.
dc.contributor.authorFeldman, Brian M.
dc.contributor.authorFerguson, Polly J.
dc.contributor.authorGewanter, Harry
dc.contributor.authorGuzman, Jaime
dc.contributor.authorKimura, Yukiko
dc.contributor.authorLee, Tzielan
dc.contributor.authorMurphy, Katherine
dc.contributor.authorNigrovic, Peter A.
dc.contributor.authorOmbrello, Michael J.
dc.contributor.authorRabinovich, C. Egla
dc.contributor.authorTesher, Melissa
dc.contributor.authorTwilt, Marinka
dc.contributor.authorKlein-Gitelman, Marisa
dc.contributor.authorBarbar-Smiley, Fatima
dc.contributor.authorCooper, Ashley M.
dc.contributor.authorEdelheit, Barbara
dc.contributor.authorGillispie-Taylor, Miriah
dc.contributor.authorHays, Kimberly
dc.contributor.authorMannion, Melissa L.
dc.contributor.authorPeterson, Rosemary
dc.contributor.authorFlanagan, Elaine
dc.contributor.authorSaad, Nadine
dc.contributor.authorSullivan, Nancy
dc.contributor.authorSzymanski, Ann Marie
dc.contributor.authorTrachtman, Rebecca
dc.contributor.authorTurgunbaev, Marat
dc.contributor.authorVeiga, Keila
dc.contributor.authorTurner, Amy S.
dc.contributor.authorReston, James T.
dc.date.accessioned2022-04-08T18:02:00Z
dc.date.available2023-05-08 14:01:58en
dc.date.available2022-04-08T18:02:00Z
dc.date.issued2022-04
dc.identifier.citationOnel, Karen B.; Horton, Daniel B.; Lovell, Daniel J.; Shenoi, Susan; Cuello, Carlos A.; Angeles-Han, Sheila T. ; Becker, Mara L.; Cron, Randy Q.; Feldman, Brian M.; Ferguson, Polly J.; Gewanter, Harry; Guzman, Jaime; Kimura, Yukiko; Lee, Tzielan; Murphy, Katherine; Nigrovic, Peter A.; Ombrello, Michael J.; Rabinovich, C. Egla; Tesher, Melissa; Twilt, Marinka; Klein-Gitelman, Marisa ; Barbar-Smiley, Fatima ; Cooper, Ashley M.; Edelheit, Barbara; Gillispie-Taylor, Miriah ; Hays, Kimberly; Mannion, Melissa L.; Peterson, Rosemary; Flanagan, Elaine; Saad, Nadine; Sullivan, Nancy; Szymanski, Ann Marie; Trachtman, Rebecca; Turgunbaev, Marat; Veiga, Keila; Turner, Amy S.; Reston, James T. (2022). "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging." Arthritis & Rheumatology 74(4): 570-585.
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://hdl.handle.net/2027.42/171978
dc.publisherWiley Periodicals, Inc.
dc.title2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171978/1/art42036-sup-0001-Disclosureform.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171978/2/art42036.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171978/3/art42036_am.pdf
dc.identifier.doi10.1002/art.42036
dc.identifier.sourceArthritis & Rheumatology
dc.identifier.citedreferenceHeijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 2013; 309: 2449 – 56.
dc.identifier.citedreferenceBaker C, Feinstein JA, Ma X, Bolen S, Dawson NV, Golchin N, et al. Variation of the prevalence of pediatric polypharmacy: a scoping review. Pharmacoepidemiol Drug Saf 2019; 28: 275 – 87.
dc.identifier.citedreferenceHydroxychloroquine. Bridgetown (Barbados): Concordia Pharmaceuticals; 2015. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf.
dc.identifier.citedreferenceWei Q, Wang W, Dong Y, Zhong L, Song H. Five years follow-up of juvenile lupus nephritis: a single-center retrospective cohort study. Ann Palliat Med 2021; 10: 7351 – 9.
dc.identifier.citedreferenceAzevedo VF, Silva MB, Marinello DK, Santos FD, Silva GB. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. Rev Bras Reumatol 2012; 52: 110 – 2.
dc.identifier.citedreferenceAdalimumab prescribing information. North Chicago: AbbVie; 2021. URL: https://www.rxabbvie.com/pdf/humira.pdf.
dc.identifier.citedreferenceRuperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383 – 91.
dc.identifier.citedreferenceAbatacept prescribing information. Princeton (NJ): Bristol Myers Squibb; 2017. URL: https://packageinserts.bms.com/pi/pi_orencia.pdf.
dc.identifier.citedreferenceTocilizumab prescribing information. San Francisco: Genentech; 2021. URL: https://www.gene.com/download/pdf/actemra_prescribing.pdf.
dc.identifier.citedreferenceDiallo A, Mekinian A, Boukari L, Mouas H, Zamy M, Nahon P, et al. Severe hepatitis in a patient with adult-onset Still’s disease treated with anakinra. Rev Med Interne 2013; 34: 168 – 70. In French.
dc.identifier.citedreferenceRuperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396 – 406.
dc.identifier.citedreferenceTofacitinib. New York: Pfizer; 2020. URL: https://labeling.pfizer.com/ShowLabeling.aspx?id=959#section-5.7.
dc.identifier.citedreferenceTuberculosis (TB): TB and Children. Centers for Disease Control and Prevention. 2021 URL: https://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm#:~:text=TB%20skin%20testing%20is%20considered,than%205%20years%20of%20age.&text=All%20children%20with%20a%20positive,should%20undergo%20a%20medical%20evaluation.
dc.identifier.citedreferenceCowger TL, Wortham JM, Burton DC. Epidemiology of tuberculosis among children and adolescents in the USA, 2007-17: an analysis of national surveillance data. Lancet Public Health 2019; 4: e506 – 16.
dc.identifier.citedreferenceGaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-γ release assay testing in children younger than 2 years in a US-based health system. Pediatr Infect Dis J 2020; 39: 803 – 7.
dc.identifier.citedreferenceBoncuoglu E, Kiymet E, Sahinkaya S, Akaslan Kara A, Caglar I, Arikan KO, et al. Usefulness of screening tests for diagnosis of latent tuberculosis infection in children. Pediatr Pulmonol 2021; 56: 1114 – 20.
dc.identifier.citedreferenceHino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 2001; 19: 3912 – 8.
dc.identifier.citedreferenceRyerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases—United States, 2009-2018. MMWR Morb Mortal Wkly Rep 2020; 69: 399 – 404.
dc.identifier.citedreferenceRobinson CL, Bernstein H, Poehling K, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 130 – 2.
dc.identifier.citedreferenceAikawa NE, Trudes G, Campos LM, Pereira RM, Moraes JC, Ribeiro AC, et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus 2013; 22: 1394 – 8.
dc.identifier.citedreferenceToplak N, Subelj V, Kveder T, Cucnik S, Prosenc K, Trampus-Bakija A, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2012; 30: 436 – 44.
dc.identifier.citedreferenceHeijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2014; 73: 1500 – 7.
dc.identifier.citedreferenceGrohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2020-21 influenza season. MMWR Recomm Rep 2020; 69: 1 – 24.
dc.identifier.citedreferenceBenchimol EI, Hawken S, Kwong JC, Wilson K. Safety and utilization of influenza immunization in children with inflammatory bowel disease. Pediatrics 2013; 131: e1811 – 20.
dc.identifier.citedreferencePapp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg 2019; 23: 50 – 74.
dc.identifier.citedreferenceOgimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011; 30: 208 – 11.
dc.identifier.citedreferenceFurer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39 – 52.
dc.identifier.citedreferenceBeukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 2773 – 80.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html.
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816 – 9.
dc.identifier.citedreferenceStrikas RA, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years—United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 93 – 4.
dc.identifier.citedreferenceRubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: 309 – 18.
dc.identifier.citedreferenceUziel Y, Moshe V, Onozo B, Kulcsar A, Trobert-Sipos D, Akikusa JD, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine 2020; 38: 2198 – 201.
dc.identifier.citedreferenceAmerican Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LK, Baker CJ, Kimberlin D, Long S, editors. Red Book: 2009 report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2009. p. 68 – 104.
dc.identifier.citedreferencePetersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarnizo JT, Beigi RH, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep 2015; 64: 1 – 26.
dc.identifier.citedreferenceOren B, Oren H, Osma E, Cevik N. Juvenile rheumatoid arthritis: cervical spine involvement and MRI in early diagnosis. Turk J Pediatr 1996; 38: 189 – 94.
dc.identifier.citedreferenceMalattia C, Damasio MB, Pistorio A, Ioseliani M, Vilca I, Valle M, et al. Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis 2011; 70: 440 – 6.
dc.identifier.citedreferenceSureda D, Quiroga S, Arnal C, Boronat M, Andreu J, Casas L. Juvenile rheumatoid arthritis of the knee: evaluation with US. Radiology 1994; 190: 403 – 6.
dc.identifier.citedreferenceDe Gonzalez AB, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004; 363: 345 – 51.
dc.identifier.citedreferenceYoung CM, Shiels WE II, Coley BD, Hogan MJ, Murakami JW, Jones K, et al. Ultrasound-guided corticosteroid injection therapy for juvenile idiopathic arthritis: 12-year care experience. Pediatr Radiol 2012; 42: 1481 – 9.
dc.identifier.citedreferenceLaurell L, Court-Payen M, Nielsen S, Zak M, Fasth A. Ultrasonography and color Doppler in juvenile idiopathic arthritis: diagnosis and follow-up of ultrasound-guided steroid injection in the wrist region. A descriptive interventional study. Pediatr Rheumatol Online J 2012; 10: 11.
dc.identifier.citedreferenceResnick CM, Vakilian PM, Kaban LB, Peacock ZS. Is intra-articular steroid injection to the temporomandibular joint for juvenile idiopathic arthritis more effective and efficient when performed with image guidance? J Oral Maxillofac Surg 2017; 75: 694 – 700.
dc.identifier.citedreferenceOnel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2022; 74: 553 – 69.
dc.identifier.citedreferenceAdnine A, Nadiri K, Soussan I, Coulibaly S, Berrada K, Najdi A, et al. Mental health problems experienced by patients with rheumatic diseases during COVID-19 pandemic. Curr Rheumatol Rev 2021; 17: 303 – 11.
dc.identifier.citedreferencePharmacy Times. FDA approves golimumab for active polyarticular juvenile idiopathic arthritis, extension of PsA indication. 2020. URL: https://www.pharmacytimes.com/news/fda-approves-golimumab-for-active-polyarticular-juvenile-idiopathic-arthritis-extension-of-psa-indication.
dc.identifier.citedreferenceUS Food and Drug Administration. News release: FDA approves first COVID-19 vaccine. 2021. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
dc.identifier.citedreferenceUS Food and Drug Administration. News release: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. 2021. URL: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.
dc.identifier.citedreferenceUS Food and Drug Administration. News release: coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. 2021. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use.
dc.identifier.citedreferenceCurtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3. Arthritis Rheumatol 2021; 73: e60 – 70.
dc.identifier.citedreferenceUS Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes for use of general anesthetic and sedation drugs in young children. 2017. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs.
dc.identifier.citedreferenceHenderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS–CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73: e13 – 29.
dc.identifier.citedreferenceBlecker U, Gold BD. Gastritis and peptic ulcer disease in childhood. Eur J Pediatr 1999; 158: 541 – 6.
dc.identifier.citedreferenceBeukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465 – 82.
dc.identifier.citedreferenceRingold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499 – 512.
dc.identifier.citedreferenceRingold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol 2019; 71: 846 – 63.
dc.identifier.citedreferenceAngeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis–associated uveitis. Arthritis Rheumatol 2019; 71: 864 – 77.
dc.identifier.citedreferenceOnel KB, Shenoi S. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis (JIA): therapeutic approaches for oligoarthritis, temporomandibular joint arthritis (TMJ), and systemic JIA, medication monitoring, immunizations and non-pharmacologic therapies. Presented at ACR Convergence; 2020 November 3–10; Atlanta, Georgia.
dc.identifier.citedreferenceAndrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines. 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013; 66: 726 – 35.
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 – 6.
dc.identifier.citedreferenceBrouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839 – 42.
dc.identifier.citedreferenceKuntze G, Nesbitt C, Whittaker JL, Nettel-Aguirre A, Toomey C, Esau S, et al. Exercise therapy in juvenile idiopathic arthritis: a systematic review and meta-analysis. Arch Phys Med Rehabil 2018; 99: 178 – 93.
dc.identifier.citedreferenceTarakci E, Arman N, Tarakci D, Kasapcopur O. Leap Motion Controller-based training for upper extremity rehabilitation in children and adolescents with physical disabilities: a randomized controlled trial. J Hand Ther 2020; 33: 220 – 8.
dc.identifier.citedreferenceDas JK, Salam RA, Thornburg KL, Prentice AM, Campisi S, Lassi ZS, et al. Nutrition in adolescents: physiology, metabolism, and nutritional needs. Ann N Y Acad Sci 2017; 1393: 21 – 33.
dc.identifier.citedreferenceBeluska-Turkan K, Korczak R, Hartell B, Moskal K, Maukonen J, Alexander DE, et al. Nutritional gaps and supplementation in the first 1000 days [review]. Nutrients 2019; 11: 2891.
dc.identifier.citedreferenceGidding SS, Dennison BA, Birch LL, Daniels SR, Gillman MW, Lichtenstein AH, et al. Dietary recommendations for children and adolescents: a guide for practitioners. Pediatrics 2006; 117: 544 – 59.
dc.identifier.citedreferenceSchrander JJ, Marcelis C, de Vries MP, van Santen-Hoeufft HM. Does food intolerance play a role in juvenile chronic arthritis? Br J Rheumatol 1997; 36: 905 – 8.
dc.identifier.citedreferenceNousiainen P, Merras-Salmio L, Aalto K, Kolho KL. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis. BMC Complement Altern Med 2014; 14: 124.
dc.identifier.citedreferenceGheita T, Kamel S, Helmy N, El-Laithy N, Monir A. Omega-3 fatty acids in juvenile idiopathic arthritis: effect on cytokines (IL-1 and TNF-α), disease activity and response criteria. Clin Rheumatol 2012; 31: 363 – 6.
dc.identifier.citedreferenceDrechsel P, Studemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, et al. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis: results from a JIA biologic registry. Rheumatology (Oxford) 2020; 59: 603 – 12.
dc.identifier.citedreferenceMeyer BM. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications. Am J Health Syst Pharm 2009; 66 Suppl: S3 – 5.
dc.identifier.citedreferenceVora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. Pediatr Rheumatol Online J 2010; 8: 11.
dc.identifier.citedreferenceFranova J, Fingerhutova S, Kobrova K, Srp R, Nemcova D, Hoza J, et al. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J 2016; 14: 36.
dc.identifier.citedreferenceKocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2009; 36: 2813 – 8.
dc.identifier.citedreferenceSingh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1 – 26.
dc.identifier.citedreferenceHunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. J Rheumatol 1997; 24: 2230 – 2.
dc.identifier.citedreferenceRavelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 625 – 7.
dc.identifier.citedreferenceSulfasalazine. New York: Pfizer; 2021. URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=524
dc.identifier.citedreferenceImundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 360 – 6.
dc.identifier.citedreferenceVan Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al, on behalf of the Dutch Juvenile Chronic Arthritis Study Group. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum 1998; 41: 808 – 16.
dc.identifier.citedreferenceTremblay L, de Chambrun GP, De Vroey B, Lavogiez C, Delaporte E, Colombel JF, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis 2011; 5: 457 – 60.
dc.identifier.citedreferenceLeflunomide prescribing information. Bridgewater (NJ): Sanofi; 2021. URL: https://products.sanofi.us/arava/arava.pdf.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
art42036-sup-0001-Disclosurefo ...
Size:
1.115MB
Format:
PDF
View/Open
Name:
art42036.pdf
Size:
597.6KB
Format:
PDF
View/Open
Name:
art42036_am.pdf
Size:
1.843MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.